Press releasePRNewswire
Armata Pharmaceuticals
ARMP · NYSE American
$3.20+$0.13 (+4.23%)TodayMarket closed ·
Prev close $3.07
Latest news
- NewsVandana Singh
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
- Press releasePRNewswire
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
- Press releasePRNewswire
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
- Press releasePRNewswire
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
- Press releasePRNewswire
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
- NewsVandana Singh
Why Is Armata Pharma Stock Gaining Monday?
- News
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia
- Press releasePRNewswire
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
- News
Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan
- Press releasePRNewswire
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
- Press releasePRNewswire
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
- Press releasePRNewswire
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
- Press releasePRNewswire
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
- Press releasePRNewswire
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
- Press releasePRNewswire
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
- Press releasePRNewswire
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
- Press releasePRNewswire
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
- Press releasePRNewswire
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
- Press releasePRNewswire
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
- Press releasePRNewswire
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
- Press releasePRNewswire
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
- Press releasePRNewswire
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why LendingClub Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
- Press releasePRNewswire
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
- Press releasePRNewswire
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.